Search

Your search keyword '"Khong, Hiep"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Khong, Hiep" Remove constraint Author: "Khong, Hiep"
24 results on '"Khong, Hiep"'

Search Results

1. Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial

2. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction

3. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

4. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy

5. Supplementary Table from Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes

6. Supplementary Figures from Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes

7. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

8. Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19

9. PRE-CLINICAL IMMUNE RESPONSE AND SAFETY EVALUATION OF THE PROTEIN SUBUNIT VACCINE NANOCOVAX FOR COVID-19

10. Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 Recombinant Spike Protein Vaccine

11. Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 Recombinant Spike Protein Vaccine

12. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes

13. Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response

14. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain

15. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

16. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

24. Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8 + T Cell Response.

Catalog

Books, media, physical & digital resources